Clinical Trial Update: Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of CDP6038 in rheumatoid arthritis patients who did not respond to anti-TNF therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CDP6038

Snippet

Sponsor: UCB Pharma | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED